MCHP
41
4
ADT
53
3
DE
63
3
SNA
68
-2
IBM
58
-2
NDAQ
62
2
APD
59
2
URBN
56
14
WDC
47
4
NRG
49
-3
HBI
59
4
SYK
64
-4
GPC
40
3
CL
58
2
TGT
22
2
INTU
56
-4
YUM
47
3
EFX
38
2
NWL
53
3
CF
57
-2
MCHP
41
4
ADT
53
3
DE
63
3
SNA
68
-2
IBM
58
-2
NDAQ
62
2
APD
59
2
URBN
56
14
WDC
47
4
NRG
49
-3
HBI
59
4
SYK
64
-4
GPC
40
3
CL
58
2
TGT
22
2
INTU
56
-4
YUM
47
3
EFX
38
2
NWL
53
3
CF
57
-2
Financhill
Back

CASI Pharmaceuticals 10K Form

Sell
29

CASI
CASI Pharmaceuticals

Last Price:
4.30
Seasonality Move:
9.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CASI News And Ratings

See the #1 stock for the next 7 days that we like better than CASI

CASI Financial Statistics

Sales & Book Value

Annual Sales: $33.88M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.90
Price / Book: 4.79

Profitability

EPS (TTM): -2.24000
Net Income (TTM): $-30.94M
Gross Margin: $20.05M
Return on Equity: -137%
Return on Assets: -47.99%

CASI Pharmaceuticals Earnings Forecast

Key CASI Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 28 years for CASI is 59.19%.
  • The Selling, General & Administrative Expenses for CASI have been equal to 123.49% of Gross Profit Margin.
  • The Research & Development expenses have been 29.11% of Revenue.
  • The Interest Expense is 2.30% of Operating Income.
  • The Net Earning history of CASI is -79.51% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 15 years.

CASI Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CASI
CUSIP: 14757U
Website: casipharmaceuticals.com

Debt

Debt-to-Equity Ratio: 1.38
Current Ratio: 3.2
Quick Ratio: 2.17

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CASI Technical Analysis vs Fundamental Analysis

Sell
29
CASI Pharmaceuticals (CASI) is a Sell

Is CASI Pharmaceuticals a Buy or a Sell?